LEXX

Lexaria to Present at The LD Micro Invitational XIV

Retrieved on: 
Thursday, March 21, 2024
Human, LEXX, Sofitel New York Hotel

Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.

Key Points: 
  • Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it will be presenting at the 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024.
  • The event is expected to feature 80 companies presenting in half-hour increments, as well as private 1:1 meetings.
  • Lexaria is scheduled to present on Tuesday April 9th, at 10:30 AM ET.
  • Chris Bunka, Chief Executive Officer of Lexaria, will discuss the Company's recent discovery of enhanced performance of glucagon-like-peptide-1 ("GLP-1") drugs utilizing DehydraTECH and the highly anticipated upcoming animal and clinical studies in humans to more thoroughly evaluate the impact of DehydraTECH processing on the world's leading GLP-1 drugs .

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Retrieved on: 
Thursday, January 11, 2024
Inflammation, LEXX, Kidney disease, Autoimmune disease, Mouth, DSM-IV codes, Tissue, Liver disease, Cancer, Ageing

With so many proven and potential blockbuster indications, enhanced delivery and increased efficacy would supercharge the impact of GLP-1 agonists.

Key Points: 
  • With so many proven and potential blockbuster indications, enhanced delivery and increased efficacy would supercharge the impact of GLP-1 agonists.
  • Lexaria Bioscience Corp. (NASDAQ: LEXX) intends to do just that with its patented DehydraTECH platform developed to improve the way active molecules enter the bloodstream upon oral ingestion.
  • DehydraTECH has demonstrated enhanced delivery of certain active molecules into brain tissue, which has particular importance for centrally active compounds via oral administration.
  • Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bioabsorption when administered intraorally (sublingual or tissues of the mouth).

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

Retrieved on: 
Tuesday, January 9, 2024
Diabetes, LEXX, Chronic kidney disease, Invention, Research, NNW, Addiction, Weight loss, Pharmaceutical industry

Obviously, diabetes remains a primary indication, given the massive global need.

Key Points: 
  • Obviously, diabetes remains a primary indication, given the massive global need.
  • However, the impact of this extraordinary molecule extends far beyond type 2 diabetes.
  • The reach of GLP-1 drugs has widened in ways its inventors likely never imagined.
  • The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

Retrieved on: 
Wednesday, January 10, 2024
Obesity, Bone density, Crohn's disease, Research, Addiction, Weight loss, History, Medicine, Amputation, Cancer, Autoimmune disease, Risk, WW International, Diarrhea, DSM-IV codes, Absorption, Liver disease, AMGN, LLY, Editorial, International, Diabetes, Amgen, GIP, Therapy, Novo Nordisk, Kidney disease, Eli Lilly and Company, Safety, Disease, Splenic infarction, Inflammation, Facial muscles, Brain, Vomiting, WW, Thought, Injection, LEXX, Weapon, Chronic kidney disease, OTCQX, GIPR, Pharmacokinetics, Patient, T2D, Nausea, Health, Paratriathlon, Partnership, SNAC, Insulin, Food, Stroke, Clinical trial, Overweight, Philosopher's stone, Ageing, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 diabetes (T2D). However, it wasn't just a milestone for T2D management. It was a turning point in medicine, opening the floodgates to a universe of potential therapeutic applications for this remarkable molecule. While undeniably transformative for diabetes and weight loss, GLP-1's reach now extends far beyond, likely surpassing even the wildest dreams of its creators. From Alzheimer's and Parkinson's to drug addiction, clinical trials are painting a stunning picture of GLP-1's versatility. And it doesn't stop there. Strong evidence points to opportunities in heart disease, chronic kidney disease and a plethora of other conditions. The newfound applications of this super-drug re-enforce the significant potential for Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its powerful DehydraTECH(TM) drug-delivery formulation and processing technology that improves both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. Lexaria joins other companies, including Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Company (NYSE: LLY), Roche (OTCQX: RHHBY) and WW International Inc. (NASDAQ: WW), that are committed to providing powerhouse solutions in the fields of diabetes, weight loss and more.

Key Points: 
  • GLP-1 agonists are among the hottest drugs in healthcare, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Lexaria Bioscience has developed DehydraTECH drug-delivery platform, which is being shown to improve pharmacokinetics of orally administered drugs.
  • Lexaria issued final data from the pilot study and is planning for multiple human and animal studies early in 2024.
  • Uncontrolled blood sugar dramatically increases the risk of devastating comorbidities, including kidney disease, vision loss, amputations, heart attacks, strokes and early death.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024
Editorial, Diabetes, Risk, CER, Fatty liver disease, Health, Nausea, Tissue, Heart, Cancer, Inflammation, Patent, Ageing, Obesity, Crohn's disease, Liver disease, LEXX, NVO, Invention, DSM-IV codes, Parkinson's disease, Pfizer, Kidney disease, Paratriathlon, European, Disease, Alzheimer's disease, Pharmacokinetics, Bone density, Merck, Facial muscles, Human, Safety, Pharma, MRK, Addiction, SNAC, AstraZeneca, PFE, DKK, Blood, Mouth, Novo Nordisk, Vomiting, Autoimmune disease, Research, Diarrhea, Weight loss, Hanmi Pharmaceutical, Weapon, Clinical trial, Refrigeration, Chronic kidney disease, Growth, Pharmaceutical industry

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Retrieved on: 
Monday, January 8, 2024
Editorial, Diabetes, Risk, CER, Fatty liver disease, Health, Nausea, Tissue, Heart, Cancer, Inflammation, Patent, Ageing, Obesity, Crohn's disease, Liver disease, LEXX, NVO, Invention, DSM-IV codes, Parkinson's disease, Pfizer, Kidney disease, Paratriathlon, European, Disease, Alzheimer's disease, Pharmacokinetics, Bone density, Merck, Facial muscles, Human, Safety, Pharma, MRK, Addiction, SNAC, AstraZeneca, PFE, DKK, Blood, Mouth, Novo Nordisk, Vomiting, Autoimmune disease, Research, Diarrhea, Weight loss, Hanmi Pharmaceutical, Weapon, Clinical trial, Refrigeration, Chronic kidney disease, Growth, Pharmaceutical industry

NEW YORK, Jan. 8, 2024 /PRNewswire/ -- Already proven to be a revolutionary treatment for type 2 diabetes and weight loss, glucagon-like peptide-1 (GLP-1) agonists now appear to have a multitude of potential blockbuster therapeutic uses, according to recent research. Obviously, diabetes remains a primary indication, given the massive global need. However, the impact of this extraordinary molecule extends far beyond type 2 diabetes. The reach of GLP-1 drugs has widened in ways its inventors likely never imagined. Clinical trials are underway testing GLP-1 drugs to treat Alzheimer's, Parkinson's, and even drug addiction, plus there are strong indications of therapeutic efficacy in heart disease and chronic kidney disease, as well as a wide range of other conditions, including weight loss. The newfound applications of this super-drug re-enforce both the reach and impact of Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile). By supercharging GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology, Lexaria intends to improve both delivery and efficacy of GLP-1 for diabetes and potentially a host of other maladies. With several key studies on the near-term horizon, Lexaria has positioned itself in the midst of these market opportunities alongside others changing the landscape, such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Novo Nordisk (NYSE: NVO).

Key Points: 
  • GLP-1 agonists are the hottest drugs in healthcare today, with uses targeting multibillion-dollar diabetes and obesity markets and much more.
  • Similarly, product sales for obesity drugs are forecast to reach $100 billion within a decade, and the most promising drugs at the head of the pack are GLP-1 agonists.
  • Novo Nordisk (NYSE: NVO) , the owner of Ozempic(R), Rybelsus(R), Victoza(R) and Wegovy(R), is a world leader in diabetes and GLP-1 drugs.
  • Companies that enhance efficacy and expand usage could prove to be the biggest winners in the progression of GLP-1 drugs.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space

Retrieved on: 
Wednesday, November 1, 2023
Research, Injection, Diabetes, Pain, Market, Human, LEXX, Appetite, Editorial, Dietary supplement

Due to the pain and unpleasantness of injections, many diabetes sufferers prefer to treat their condition with drugs rather than devices, if they have the choice.

Key Points: 
  • Due to the pain and unpleasantness of injections, many diabetes sufferers prefer to treat their condition with drugs rather than devices, if they have the choice.
  • Some of the most popular type 2 diabetes in recent years are GLP-1 (glucagon-like peptide-1) receptor agonists.
  • They work by mimicking the effects of the naturally occurring hormone GLP-1, which helps to regulate blood sugar levels and appetite.
  • With such positive early results, Lexaria is expanding its diabetes study program, including using DehydraTECH for GLP-1 drugs alone and in combination with other molecules.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Retrieved on: 
Tuesday, October 31, 2023
Weight loss, Singing, NNW, Blood, Diabetes, Human, LEXX, Glucose, Obesity, Dietary supplement

GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity.

Key Points: 
  • GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity.
  • But there may be an even better avenue to increased effectiveness and better outcomes.
  • Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight.
  • With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution

Retrieved on: 
Thursday, August 11, 2022
NNW, GLOBE, Death, SMS, PDE5, Research, Cannabinoid, Overload, Nicotine, NASDAQ, Social media, News, Hypertension, LEXX, Solution, API, Editorial, Online shopping, Pharmaceutical industry, Science

All told, hypertension costs the country on average $131 billion annually, and even more sobering, in 2020 alone, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.

Key Points: 
  • All told, hypertension costs the country on average $131 billion annually, and even more sobering, in 2020 alone, more than 670,000 deaths in the United States had hypertension as a primary or contributing cause.
  • A recognized global innovator in drug-delivery platforms, Lexaria Bioscience Corp. (NASDAQ: LEXX) is determined to fill the need for a safe, effective, tolerable treatment for hypertension and have a meaningful impact on comorbidity-related costs and deaths.
  • Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and more than 50 patents pending worldwide.
  • By cutting through the overload of information in todays market, NNW brings its clients unparalleled visibility, recognition and brand awareness.